Chinanews Client Beijing, April 9th ​​(Reporter Zhang Ni) A few days ago, Feng Duojia, President of China Vaccine Industry Association, revealed to the media that the mission goal by the end of next year is to hope that China's new crown vaccine will have an annual production capacity of 5 billion doses. Meet the vaccination needs of nearly 70% of the domestic population before the end of this year.

The picture shows citizens vaccinated against the new coronavirus.

Photo by Yu Jing

Before the end of the year, domestic vaccine production capacity can meet 70% of Chinese people's vaccination

　　At present, the new crown vaccination is steadily advancing in China.

　　According to data from the National Health Commission, as of April 8, 2021, 31 provinces (autonomous regions, municipalities) and the Xinjiang Production and Construction Corps have reported a total of 15.515 million doses of new crown virus vaccine.

　　However, this data is still far from the "universal" 70%-80% vaccination rate.

The speed of vaccination work and the production capacity of vaccines have become the most concerned issues of the outside world.

　　"The mission goal by the end of next year is to hope that China's new crown vaccine will have an annual production capacity of 5 billion doses. By the end of this year, nearly 70% of the domestic population will be vaccinated, while also meeting almost the same proportion of the foreign market."

　　At the fifth Peking University Global Health and Innovation Communication Seminar held a few days ago, Feng Duojia disclosed such news.

　　At the same time, with the help of the World Health Organization's Emergency Use List (WHO EUL) program, China's new crown vaccine has obtained a platform for international services.

　　Yuan Yuan, the national representative of the Shanghai Representative Office of PATH, a non-profit international organization, introduced that in 2017, the World Health Organization clarified the WHO EUL procedures, with the purpose of providing products to those affected by public health emergencies as soon as possible. people.

Of the 18 new coronavirus vaccines currently applying for WHO EUL, 7 are from China, which is more than 1/3.

　　"China's vaccine has long-term responsibility for providing global public products and services. China's new crown vaccine's industrial manufacturing capacity has accounted for about half of the global new crown vaccine production capacity, and it has great potential to contribute to global health." Feng Duojia Said.

Data map: Pre-filled syringes on the packaging line for vaccines.

Photo by China News Agency reporter Hou Yu

China's

transformation from a vaccine power to a vaccine power

　　In the opinion of industry experts, China's vaccine industry is currently undergoing an important change.

　　Experts pointed out that the domestic new crown vaccine has played an important role in filling the gap in the new crown vaccine, and the development of the new crown vaccine has also led to the internationalization of China's vaccine industry.

　　"This new crown epidemic has also greatly promoted the accelerated upgrading of China's vaccine industry industrial chain." Feng Duojia emphasized.

　　According to reports, there are currently more than 300 member units of the Vaccine Industry Association. Except for nearly 100 companies that specialize in vaccine research, production and cold chain supply, most companies provide supporting services around the vaccine industry chain. Equipment, materials, equipment, engineering, information services, and even investment and financing including media communication services, legal consulting services, education, culture, publicity broadcasting services, etc.

　　Feng Duojia said that a complete industrial chain has been gradually formed in China, and these industrial chains have been accompanied by Chinese vaccines going overseas, and all enterprises are accelerating the upgrading of production capacity and quality.

At the same time, this process promotes technological innovation and the enhancement of independent guarantee capabilities.

　　According to Feng Duojia's analysis, the new crown epidemic has brought unprecedented development opportunities to China's vaccine industry, and it has also posed unprecedented challenges to the development and supply of vaccines.

　　In the future, bringing vaccine products and services in line with international standards in the entire process and all elements, and having strong vaccine industry capabilities and production efficiency is the key to accelerating the internationalization process of China's vaccine industry and achieving "excellent" and "strong".

　　"China's vaccines are accelerating the historic transformation from a major vaccine country to a strong vaccine country, both in terms of quality and output." Feng Duojia said.

(Finish)